MARKET

PAVM

PAVM

Pavmed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.010
+0.022
+2.23%
After Hours: 1.020 +0.01 +0.99% 17:31 05/26 EDT
OPEN
0.9900
PREV CLOSE
0.9880
HIGH
1.040
LOW
0.9700
VOLUME
981.02K
TURNOVER
0
52 WEEK HIGH
9.70
52 WEEK LOW
0.9400
MARKET CAP
88.85M
P/E (TTM)
-1.3843
1D
5D
1M
3M
1Y
5Y
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
NEW YORK, May 13, 2022--PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO.
Business Wire · 05/13 12:25
PAVmed: Q1 Earnings Insights
PAVmed (NASDAQ:PAVM) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings PAVmed beat estimated earnings by 30.0%, reporting an EPS of $-0.14 versus an estimate of $-0.2...
Benzinga · 05/12 22:43
PAVmed Non-GAAP EPS of -$0.14 beats by $0.05, revenue of $0.2M misses by $0.15M
PAVmed press release (NASDAQ:PAVM): Q1 Non-GAAP EPS of -$0.14 beats by $0.05. Revenue of $0.2M misses by $0.15M.
Seekingalpha · 05/12 20:49
PAVmed Q1 Adj. EPS $(0.14) Beats $(0.20) Estimate, Sales $189.00K Miss $350.00K Estimate
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 75 percent decrease over losses of $(0.08) per share from the same period
Benzinga · 05/12 20:40
PAVmed Q1 2022 Earnings Preview
PAVmed (NASDAQ:PAVM) is scheduled to announce Q1 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.19 (vs. -$0.08 last year) and the consensus Revenue
Seekingalpha · 05/11 21:35
BRIEF-Lucid Diagnostics Reports Q1 Preliminary Adjusted Loss Per Share Of $0.23
reuters.com · 05/11 20:01
BRIEF-Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement With MediNcrease Health Plans
reuters.com · 05/09 12:44
Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study
Veeva Systems (NYSE: VEEV) today announced that Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), has selected Veeva Vault CDMS to p...
PR Newswire · 05/04 11:03
More
No Data
Learn about the latest financial forecast of PAVM. Analyze the recent business situations of Pavmed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PAVM stock price target is 6.38 with a high estimate of 9.50 and a low estimate of 4.000.
High9.50
Average6.38
Low4.000
Current 1.010
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 115
Institutional Holdings: 26.65M
% Owned: 30.29%
Shares Outstanding: 87.97M
TypeInstitutionsShares
Increased
33
3.33M
New
29
5.85M
Decreased
32
2.48M
Sold Out
30
3.68M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.61%
Healthcare Equipment & Supplies
+0.56%
Key Executives
Chairman/Chief Executive Officer/Director
Lishan Aklog
President/Chief Financial Officer/Secretary
Dennis Mcgrath
Non-Executive Vice Chairman/Independent Director
Michael Glennon
Chief Operating Officer/Executive Vice President
Shaun Oneil
Other
Brian DeGuzman
Director
Tim Baxter
Director
Joan Harvey
Director
Debra White
Independent Director
James Cox
Independent Director
Ronald Sparks
Independent Director
David Weild
No Data
No Data
About PAVM
PAVmed Inc. is a multi-product, commercial-stage technology medical device company. The Company has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.

Webull offers kinds of PAVmed Inc stock information, including NASDAQ:PAVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PAVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PAVM stock methods without spending real money on the virtual paper trading platform.